Edesa Biotech, Inc.

NASDAQ:EDSA

Biotechnology

Healthcare
$5.75 +1.31%

+$0.09 today

Market cap
$55.39M
Beta
1.07
P/E (TTM)
-5.5
EPS (TTM)
-$1.27
52W Low $0.72High $20.32

Volume 0.07M

Average 0.62M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$7.32M

FY 2025 · Annual

Investing Cash Flow

$0.00

FY 2025 · Annual

Financing Cash Flow

$17.03M

FY 2025 · Annual

+2776.7% YoY

Cash Flow Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Net Income(13.34M)(17.55M)(8.37M)(6.17M)(7.19M)
Depreciation & Amortization118.79K118.19K183.47K186.05K119.27K
Deferred Income Tax(3.31M)(2.38M)(308K)00
Stock-Based Compensation3.2M2.26M1.25M537.49K729.64K
Change in Working Capital(3.64M)2.89M308K571.07K(985.65K)
Accounts Receivables(3.23M)2.03B562.77K356.34K(377.99K)
Inventory00000
Accounts Payables(124.72K)882.84K(556.27K)00
Other Working Capital(281.36K)(2.03B)301.5K214.73K(607.67K)
Other Non-Cash Items3.31M2.38M308K(14.77K)0
Operating Cash Flow(13.66M)(12.28M)(6.64M)(4.89M)(7.32M)
Capital Expenditures(6.15K)(5.66K)300
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00(3)00
Investing Cash Flow(6.15K)(5.66K)000
Debt Repayment000(29.53K)0
Common Stock Issued14.17M11.63M4.83M621.56K17.03M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00000
Financing Cash Flow14.17M11.63M4.83M592.03K17.03M
Effect of Forex Changes121.9K(93.01K)76.85K(25.9K)46.22K
Net Change in Cash625.56K(748.34K)(1.73M)(4.32M)9.75M
Free Cash Flow(13.67M)(12.28M)(6.64M)(4.89M)(7.32M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$7.2M
+ D&A$119.3K
+ Stock-Based Comp$729.6K
+ Deferred Tax$0
- Working Capital-$985.7K
+ Other Non-Cash$0
= Operating Cash Flow-$7.3M
- Capex$0
= Free Cash Flow-$7.3M

Analysis

FY2025 free cash flow is -$7.3M. FCF conversion is 101.9% of net income. Operating cash flow was -$7.3M, with capex of $0. The largest bridge item is Working Capital at -$985.7K.

Competitors

Peer companies in the same sector

Health

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipAug 4, 2026
EFFECTEFFECT filingJul 13, 2026
424B3424B3 filingJul 13, 2026
4Statement of changes in beneficial ownershipJul 2, 2026
S-3S-3 filingJul 2, 2026

Does EDSA generate free cash flow?

Edesa Biotech, Inc. (EDSA) generated -$7.32M of free cash flow in fiscal 2025.

How much operating cash flow does EDSA produce?

Operating cash flow was -$7.32M, before capital expenditures of $0.00.